Clinical Trial Update: Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines [Phase 2]

View source ↗

Summary

Phase 2 trial update characterizes the immune responses to two experimental malaria vaccines developed by GlaxoSmithKline; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Experimental malaria vaccine A
• Experimental malaria vaccine B

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 2 | Status: COMPLETED